The potential for targeting IL13Rα2-expressing GBMs has been demonstrated by early clinical experience at City of Hope in two phase I clinical trials with intracranial administration of first-generation IL13 zetakine T cell clones in patients with high-grade gliomas. The gene discussed is IL13RA2; the disease is glioma.